Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

(Image Credit: AdobeStock/tadamichi) Sight Sciences announced that its TearCare System has been included in the new Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS) published in the American Journal of Ophthalmology.1,2 This marks the…

(Image Credit: AdobeStock) Outlook Therapeutics has requested a Type A meeting with the US Food and Drug Administration following the agency issuing a complete response letter (CRL) to its biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment…

(Image credit: AdobeStock/vetrana) The annual scientific meeting of the American Society of Retina Specialists (ASRS) was held in Long Beach, California from July 30 through August 2, 2025. At this event, researchers and experts in the retina field shared data…

(Image credit: AdobeStock/Pete) The European Medicines Agency (EMA) granted Orphan designations to MCO-010 (sonpiretigene isteparvovec) across 5 categories of retinal dystrophies. The US Food and Drug Administration (FDA) also granted RMAT designation for MCO-010 in Stargardt disease (SD). The EMA…
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences The Manila Times Source: Author: | Date: 2025-09-01 08:15:00 Source: Author: | Date: 2025-09-01 08:15:00
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences Yahoo Finance Source: Author: | Date: 2025-09-01 08:00:00 Source: Author: | Date: 2025-09-01 08:00:00
Regenerons $0.33 Billion Trading Day 287th in Activity as Sepsis Trial Advances and Eylea HD Approval Drive Mixed Investor Signals AInvest Source: Author: | Date: 2025-08-29 23:47:00 Source: Author: | Date: 2025-08-29 23:47:00

(Image Credit: AdobeStock) The recent OMEGA study1 found that “inferred sensitivity” mapping may be a potential functional surrogate end point for geographic atrophy (GA) based on its ability to predict retinal function with high spatial resolution and without extensive psychophysical…

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Outlook Therapeutics’ biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD). The recent CRL included only 1 deficiency, for…

(Image credit: AdobeStock/Pixel-Shot) A study published in Ophthalmology Science shows that by analyzing up-to daily home OCT images, artificial intelligence (AI) can accurately track disease activity in patients with wet age-related macular degeneration (AMD). This may allow physicians to manage…